Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 656-668

  Wang, Guan ^a,b   Niu, Xiaojia ^a   Zhang, Wenbo ^a   Caldwell, J Timothy ^b   Edwards, Holly ^b   Chen, Wei ^b   Taub, Jeffrey W ^b,c   Zhao, Lijing ^a   Ge, Yubin ^a,b  

^a JILIN UNIVERSITY   (China)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

CHK1; Drug combination; MK 1775; Pancreatic cancer; Panobinostat

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; HISTONE H2AX; PANOBINOSTAT; RABUSERTIB; CELL CYCLE PROTEIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE; MESSENGER RNA; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SMALL INTERFERING RNA; WEE1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG INTERACTION; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; DNA DAMAGE; DRUG INTERACTIONS; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOENZYME TECHNIQUES; INDOLES; MICE; MICE, INBRED BALB C; MICE, NUDE; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919494726     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.10.015     Document Type: Article

References (49)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol 1997, 15:2403-2413.
3. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med 2011, 364:1817-1825.
4. Parker L.L., Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 1992, 257:1955-1957.
5. Watanabe N., Broome M., Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 1995, 14:1878-1891.
6. Sanchez Y., Wong C., Thoma R.S., Richman R., Wu Z., Piwnica-Worms H., et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997, 277:1497-1501.
7. Peng C.Y., Graves P.R., Thoma R.S., Wu Z., Shaw A.S., Piwnica-Worms H. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 1997, 277:1501-1505.
8. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000, 14:1448-1459.
9. Zhao H., Piwnica-Worms H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol 2001, 21:4129-4139.
10. Hirai H., Iwasawa Y., Okada M., Arai T., Nishibata T., Kobayashi M., et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther 2009, 8:2992-3000.
11. Aarts M., Sharpe R., Garcia-Murillas I., Gevensleben H., Hurd M.S., Shumway S.D., et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012, 2:524-539.
12. Bridges K.A., Hirai H., Buser C.A., Brooks C., Liu H., Buchholz T.A., et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res 2011, 17:5638-5648.
13. Chaudhuri L., Vincelette N.D., Koh B.D., Naylor R.M., Flatten K.S., Peterson K.L., et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica 2014, 99:688-696.
14. Guertin A.D., Li J., Liu Y., Hurd M.S., Schuller A.G., Long B., et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol. Cancer Ther 2013, 12:1442-1452.
15. Hirai H., Arai T., Okada M., Nishibata T., Kobayashi M., Sakai N., et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol. Ther 2010, 9:514-522.
16. Kreahling J.M., Foroutan P., Reed D., Martinez G., Razabdouski T., Bui M.M., et al. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS ONE 2013, 8:e57523.
17. Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res 2011, 17:2799-2806.
18. Van Linden A.A., Baturin D., Ford J.B., Fosmire S.P., Gardner L., Korch C., et al. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol. Cancer Ther 2013, 12:2675-2684.
19. Krajewska M., Heijink A.M., Bisselink Y.J., Seinstra R.I., Sillje H.H., de Vries E.G., et al. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene 2013, 32:3001-3008.
20. Byrd J.C., Marcucci G., Parthun M.R., Xiao J.J., Klisovic R.B., Moran M., et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005, 105:959-967.
21. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112:981-989.
22. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008, 111:1060-1066.
23. Giles F., Fischer T., Cortes J., Garcia-Manero G., Beck J., Ravandi F., et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res 2006, 12:4628-4635.
24. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol 2008, 81:170-176.
25. Gojo I., Jiemjit A., Trepel J.B., Sparreboom A., Figg W.D., Rollins S., et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007, 109:2781-2790.
26. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res 2008, 14:826-832.
27. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006, 106:112-119.
28. Xie C., Drenberg C., Edwards H., Caldwell J.T., Chen W., Inaba H., et al. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS ONE 2013, 8:e79106.
29. Wang G., Edwards H., Caldwell J.T., Buck S.A., Qing W.Y., Taub J.W., et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS ONE 2013, 8:e76662.
30. Xie C., Edwards H., Xu X., Zhou H., Buck S.A., Stout M.L., et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin. Cancer Res 2010, 16:5499-5510.
31. Xie C., Edwards H., Lograsso S.B., Buck S.A., Matherly L.H., Taub J.W., et al. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr. Blood Cancer 2012, 59:1245-1251.
32. Carrassa L., Chila R., Lupi M., Ricci F., Celenza C., Mazzoletti M., et al. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle 2012, 11:2507-2517.
33. Davies K.D., Cable P.L., Garrus J.E., Sullivan F.X., von Carlowitz I., Huerou Y.L., et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol. Ther 2011, 12:788-796.
34. Guertin A.D., Martin M.M., Roberts B., Hurd M., Qu X., Miselis N.R., et al. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition. Cancer Cell Int 2012, 12:45.
35. Chen S., Wang G., Niu X., Zhao J., Tan W., Wang H., et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett 2014, 348:20-28.
36. Xu X., Xie C., Edwards H., Zhou H., Buck S.A., Ge Y. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS ONE 2011, 6:e17138.
37. Ge Y., Dombkowski A.A., LaFiura K.M., Tatman D., Yedidi R.S., Stout M.L., et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 2006, 107:1570-1581.
38. Wang G., He J., Zhao J., Yun W., Xie C., Taub J.W., et al. and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE 2012, 7:e52095.
39. Edwards H., Xie C., LaFiura K.M., Dombkowski A.A., Buck S.A., Boerner J.L., et al. RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood 2009, 114:2744-2752.
40. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics 1982, 38:963-974.
41. J. Pinheiro, B. Bates, S. DebRoy, D. Sarkar, R Package Version 3, 2005.
42. Tibes R., Bogenberger J.M., Chaudhuri L., Hagelstrom R.T., Chow D., Buechel M.E., et al. RNAi screening of the kinome with cytarabine in leukemias. Blood 2012, 119:2863-2872.
43. Leijen S., Schellens J.H., Shapiro G., Pavlick A.C., Tibes R., Demuth T., et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol 2010, 28:3067.
44. Russell M.R., Levin K., Rader J., Belcastro L., Li Y., Martinez D., et al. Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Res 2013, 73:776-784.
45. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
46. Brazelle W., Kreahling J.M., Gemmer J., Ma Y., Cress W.D., Haura E., et al. Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS ONE 2010, 5:e14335.
47. Scuto A., Kirschbaum M., Kowolik C., Kretzner L., Juhasz A., Atadja P., et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood 2008, 111:5093-5100.
48. Hideshima T., Richardson P.G., Anderson K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther 2011, 10:2034-2042.
49. Rothblum-Oviatt C.J., Ryan C.E., Piwnica-Worms H. 14-3-3 binding regulates catalytic activity of human Wee1 kinase. Cell Growth Differ 2001, 12:581-589.